Brooke Shields convenes other celebrities, influencers and patient advocates over 50 to discuss the power of aging and how to protect their health Shields directs a short film, encouraging adults 50 ...
GSK will continue evaluating long-term data and conducting real-world studies for its shingles vaccine efficacy, immunogenicity, and safety. GSK's gepotidacin was non-inferior to a leading combination ...
Emma Walmsley and her GSK CEO successor, Luke Miels, are safeguarding the British pharma’s 40-billion-pound sales projection ...
The news on vaccines was not so good, as declining sales of shingles shot Shingrix in the US and China pegged back growth to ...
GSK (NYSE:GSK) said a long-term followup study showed that its top-selling shingles vaccine, Shingrix, had a 79.7% efficacy rate six to 11 years after vaccination in people aged 50 and older. Results ...
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
This summer, GSK cut its yearly vaccine sales projection on the back of a narrowed recommendation for adult respiratory syncytial virus (RSV) vaccines from the Centers for Disease Control and ...
GSK said the forecasts were “inclusive of tariffs enacted thus far and indicated potential European tariffs' impact of 15 per ...
GSK takes advantage of natural experiment to study whether shingles vaccine can reduce dementia risk
After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of a natural experiment to look for more definitive evidence that the shot ...
A recent study shows adults with cardiovascular disease (CVD) have a higher risk of developing shingles. People who have two ...
(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback